Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

NewAmsterdam Pharma Company N.V. Ordinary Shares

Healthcare US NAMS

32.67USD
0.56(1.74%)

Last update at 2026-06-04T20:01:00Z

Day Range

32.1233.42
LowHigh

52 Week Range

5.6326.35
LowHigh

Fundamentals

  • Previous Close 32.11
  • Market Cap1746.62M
  • Volume1384246
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-198.54099M
  • Revenue TTM6.86M
  • Revenue Per Share TTM0.08
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -78.05200M -28.59900M -5.74900M
Minority interest - - -
Net income -148.88400M -28.81500M -6.09300M
Selling general administrative 18.14M 3.94M 1.37M
Selling and marketing expenses 3.75M 0.71M 0.01M
Gross profit 97.50M - -
Reconciled depreciation 0.07M 0.01M 0.00100M
Ebit -67.56000M -29.82600M -5.42900M
Ebitda -6.87700M -29.81200M -5.42800M
Depreciation and amortization 60.68M 0.01M 0.00100M
Non operating income net other - - -
Operating income -67.56000M -29.82600M -5.42900M
Other operating expenses 104.46M 29.84M 5.43M
Interest expense 0.27M 0.22M 0.34M
Tax provision 0.00000M 0.00000M 0.00000M
Interest income 0.01M 0.00900M 0.00000M
Net interest income -0.26000M -0.20700M -0.34400M
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense 70.83M 0.22M 0.34M
Total revenue 97.50M 0.00000M 0.00000M
Total operating expenses 104.46M 29.84M 5.43M
Cost of revenue - - -
Total other income expense net -10.49200M 1.23M -0.32000M
Discontinued operations - - -
Net income from continuing ops -78.05200M -28.59900M -5.74900M
Net income applicable to common shares - -28.59900M -5.74900M
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 347.10M 531.58M 59.78M 9.23M
Intangible assets 0.17M - - -
Earning assets - - - -
Other current assets 6.34M - 1.49M 1.36M
Total liab 58.70M 47.06M 9.99M 12.81M
Total stockholder equity 288.39M 484.52M 49.79M -3.57700M
Deferred long term liab - - - -
Other current liab 23.97M 11.28M 0.00100M 0.76M
Common stock 10.17M 599.19M 83.88M 2.50M
Capital stock 10.17M 599.19M 83.88M 2.50M
Retained earnings -316.97300M -119.36100M -34.67600M -6.07700M
Other liab - - - -
Good will - - - -
Other assets - - 0.72M -
Cash 340.45M 438.52M 53.09M 7.86M
Cash and equivalents - - - -
Total current liabilities 49.90M 35.46M 9.88M 12.81M
Current deferred revenue 8.94M 13.01M 3.61M -
Net debt -340.39000M -438.40400M -52.92800M 3.79M
Short term debt 0.06M 0.06M 0.05M 11.65M
Short long term debt - - - 11.65M
Short long term debt total 0.06M 0.12M 0.16M 11.65M
Other stockholder equity 273.80M - 0.59M -
Property plant equipment - - 0.19M 0.01M
Total current assets 346.79M 448.13M 58.87M 9.22M
Long term investments - - - -
Net tangible assets - - 49.79M -3.57700M
Short term investments - - - -
Net receivables 1.88M 1.94M 4.29M -
Long term debt - - - -
Inventory -1.88100M - - -
Accounts payable 16.92M 11.11M 6.22M 0.40M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income 4.42M 4.69M 0.59M -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.04M 0.15M 0.72M -
Deferred long term asset charges - - - -
Non current assets total 0.31M 83.45M 0.91M 0.01M
Capital lease obligations 0.06M 0.12M 0.16M 0.00000M
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments 0.71M -0.02000M -0.01300M
Change to liabilities - 8.25M 0.83M
Total cashflows from investing activities - -0.02000M -0.01300M
Net borrowings - -0.01000M 11.32M
Total cash from financing activities 375.18M 68.99M 11.32M
Change to operating activities - -4.42400M -1.35700M
Net income -78.05200M -28.59900M -5.74900M
Change in cash 385.43M 45.23M 5.36M
Begin period cash flow 53.09M 7.86M 2.50M
End period cash flow 438.52M 53.09M 7.86M
Total cash from operating activities 7.97M -25.16400M -5.97000M
Issuance of capital stock 377.78M 69.00M 0.00000M
Depreciation 0.07M 0.01M 0.00100M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock - - -
Other cashflows from financing activities -2.53400M -0.02000M -0.01300M
Change to netincome - -0.40100M 0.31M
Capital expenditures 0.01M 0.02M 0.01M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 11.46M 3.82M -0.52800M
Stock based compensation 3.92M 1.05M 0.00000M
Other non cash items 70.57M -0.00700M 0.31M
Free cash flow 7.96M -25.18400M -5.98300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares		 0.56 1.74% 32.67 - - 124.81 6.13 101.29 -8.0691
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V. Ordinary Shares

Gooimeer 2-35, Naarden, Netherlands, 1411 DC

Key Executives

Name Title Year Born
Dr. Michael Harvey Davidson FACC, Facc., Facp., M.D. CEO, Pres, Exec. Board Member & Director 1957
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. Founder, Chief Scientific Officer & Member of Exec. Board 1954
Ms. Louise Kooij CFO, Treasurer, Member of Exec. Board & Director NA
Mr. Douglas F. Kling COO, VP & Director 1973
Mr. Jim Jacobson Chief Legal Officer & Sec. NA
Ms. Lina Gugucheva Chief Bus. Officer NA
Dr. Sheng Cui Ph.D. VP & Head of Chemistry Manufacturing and Controls (CMC) NA
Ms. Annie Neild VP & Head of Regulatory Affairs NA
Dr. Michael Harvey Davidson FACC, Facp., M.D. CEO, President, Executive Board Member & Director 1956
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. Founder, Chief Scientific Officer, Member of Executive Board & Director 1954

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.